|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5(66)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kaleem M, Gangane P, Mujtaba MA, Kanekar
A, Shahzad N, Alzahrani AR, Zafar A and Ahmad A: The advancements
in targeted therapeutic strategies for breast cancer via
intervention of natural molecules: An insight into cellular and
molecular mechanisms. Pathol Res Pract. 278(156338)2026.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Deeptha TC, Nabeela NK, Pushparaj C,
Narayanasamy A, Manickam P, Thiruvenkataswamy S and Sennimalai R:
Novel therapeutic approaches targeting cancer stem cells: Unveiling
new frontiers in breast cancer treatment. Pathol Res Pract.
266(155800)2025.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tang Y, Zang H, Wen Q and Fan S: AXL in
cancer: A modulator of drug resistance and therapeutic target. J
Exp Clin Cancer Res. 42(148)2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Liu Y, Xu L, Dou Y and He Y: AXL: Shapers
of tumor progression and immunosuppressive microenvironments. Mol
Cancer. 24(11)2025.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhu C, Wei Y and Wei X: AXL receptor
tyrosine kinase as a promising anti-cancer approach: Functions,
molecular mechanisms and clinical applications. Mol Cancer.
18(153)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Qian C, Wang C and Liu F: AXL in
cardiovascular diseases: Pathophysiological insights and clinical
perspectives. Pathol Res Pract. 272(156120)2025.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gjerdrum C, Tiron C, Høiby T, Stefansson
I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT,
et al: Axl is an essential epithelial-to-mesenchymal
transition-induced regulator of breast cancer metastasis and
patient survival. Proc Natl Acad Sci USA. 107:1124–1129.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ji J, Ding Y, Kong Y, Fang M, Yu X, Lai X
and Gu Q: Triple-negative breast cancer cells that survive ionizing
radiation exhibit an Axl-dependent aggressive radioresistant
phenotype. Exp Ther Med. 26(448)2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chang H, An R, Li X, Lang X, Feng J and Lv
M: Anti-Axl monoclonal antibodies attenuate the migration of
MDA-MB-231 breast cancer cells. Oncol Lett. 22(749)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang G, Wang M, Zhao H and Cui W:
Function of Axl receptor tyrosine kinase in non-small cell lung
cancer. Oncol Lett. 15:2726–2734. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yadav M, Sharma A, Patne K, Tabasum S,
Suryavanshi J, Rawat L, Machaalani M, Eid M, Singh RP, Choueiri TK,
et al: AXL signaling in cancer: From molecular insights to targeted
therapies. Signal Transduct Target Ther. 10(37)2025.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Eriksen Gjerstad M, Aehnlich P, Gelebart P
and Mc Cormack E: AXL tyrosine kinases: A growing isoform family
that promotes cancer pathogenesis. Cancer Res. 85:2561–2573.
2025.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang G, Hou S, Li S, Wang Y and Cui W:
Role of STAT3 in cancer cell epithelial-mesenchymal transition
(review). Int J Oncol. 64(48)2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ma JH, Qin L and Li X: Role of STAT3
signaling pathway in breast cancer. Cell Commun Signal.
18(33)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Qin JJ, Yan L, Zhang J and Zhang WD: STAT3
as a potential therapeutic target in triple negative breast cancer:
A systematic review. J Exp Clin Cancer Res. 38(195)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Meyer AS, Miller MA, Gertler FB and
Lauffenburger DA: The receptor AXL diversifies EGFR signaling and
limits the response to EGFR-targeted inhibitors in triple-negative
breast cancer cells. Sci Signal. 6(ra66)2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang G, Kong X, Wang M, Zhao H, Han S, Hu
R, Huang J and Cui W: AXL is a marker for epithelial-mesenchymal
transition in esophageal squamous cell carcinoma. Oncol Lett.
15:1900–1906. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Khera L, Vinik Y, Maina F and Lev S: The
AXL-PYK2-PKCα axis as a nexus of stemness circuits in TNBC. Life
Sci Alliance. 4(e202000985)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kim TH, Lee D, Oh HJ, Ham IH, Tran TT, Lee
Y, Kim TM, Brekken RA, Zhang Z, Ke D and Hur H: Cancer-associated
fibroblast-derived GAS6 increases resistance to chemotherapy
through AXL/STAT3/ABCG1 in gastric cancer. Br J Cancer. 134:72–84.
2026.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hung CN, Chen M, DeArmond DT, Chiu CH,
Limboy CA, Tan X, Kusi M, Chou CW, Lin LL, Zhang Z, et al:
AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal
and vasculogenic supportive features of tumor-associated
macrophages. Cell Rep. 42(113067)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sun X, Chen H, You S, Tian Z, Wang Z, Liu
F, Hu W, Zhang H, Zhang G, Zhao H and Guo Q: AXL upregulates c-Myc
expression through AKT and ERK signaling pathways in breast
cancers. Mol Clin Oncol. 18(22)2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Han S, Wang Y, Ge C, Gao M, Wang X, Wang
F, Sun L, Li S, Dong T, Dang Z, et al: Pharmaceutical inhibition of
AXL suppresses tumor growth and invasion of esophageal squamous
cell carcinoma. Exp Ther Med. 20(41)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Cheng SH, Huang TT, Cheng YH, Tan TBK,
Horng CF, Wang YA, Brian NS, Shih LS and Yu BL: Validation of the
18-gene classifier as a prognostic biomarker of distant metastasis
in breast cancer. PLoS One. 12(e0184372)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chanrion M, Negre V, Fontaine H, Salvetat
N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F,
Theillet C and Darbon JM: A gene expression signature that can
predict the recurrence of tamoxifen-treated primary breast cancer.
Clin Cancer Res. 14:1744–1752. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47 (W1):W556–W560.
2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Su YF, Shen PC, Huang WY, Hung YJ, Huang
TW, Lin CY and Shieh YS: Nuclear translocation of Axl contributes
to the malignancy of oral cancer cells. J Dent Sci. 19:438–447.
2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hu Y, Dong Z and Liu K: Unraveling the
complexity of STAT3 in cancer: Molecular understanding and drug
discovery. J Exp Clin Cancer Res. 43(23)2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kim LC, Song L and Haura EB: Src kinases
as therapeutic targets for cancer. Nat Rev Clin Oncol. 6:587–595.
2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chocarro-Calvo A, Jociles-Ortega M,
García-Martinez JM, Louphrasitthiphol P, Carvalho-Marques S,
Vivas-García Y, Ramírez-Sánchez A, Chauhan J, Fiuza MC, Duran M, et
al: Fatty acid uptake activates an AXL-CAV1-β-catenin axis to drive
melanoma progression. Genes Dev. 39:463–489. 2025.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Dong M, Xiao Q, Hu J, Cheng F, Zhang P,
Zong W, Tang Q, Li X, Mao F, He Y, et al: Targeting LRIG2 overcomes
resistance to EGFR inhibitor in glioblastoma by modulating
GAS6/AXL/SRC signaling. Cancer Gene Ther. 27:878–897.
2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Xiao Y, Zhao H, Tian L, Nolley R, Diep AN,
Ernst A, Fuh KC, Miao YR, von Eyben R, Leppert JT, et al: S100A10
is a critical mediator of GAS6/AXL-induced angiogenesis in renal
cell carcinoma. Cancer Res. 79:5758–5768. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Banerjee K and Resat H: Constitutive
activation of STAT3 in breast cancer cells: A review. Int J Cancer.
138:2570–2578. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ozyurt R and Ozpolat B: Therapeutic
landscape of AXL receptor kinase in triple-negative breast cancer.
Mol Cancer Ther. 22:818–832. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Khera L and Lev S: Accelerating AXL
targeting for TNBC therapy. Int J Biochem Cell Biol.
139(106057)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zajac O, Leclere R, Nicolas A, Meseure D,
Marchiò C, Vincent-Salomon A, Roman-Roman S, Schoumacher M and
Dubois T: AXL controls directed migration of mesenchymal
triple-negative breast cancer cells. Cells. 9(247)2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Holland SJ, Pan A, Franci C, Hu Y, Chang
B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, et al: R428, a
selective small molecule inhibitor of Axl kinase, blocks tumor
spread and prolongs survival in models of metastatic breast cancer.
Cancer Res. 70:1544–1554. 2010.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Loges S, Heuser M, Chromik J, Sutamtewagul
G, Kapp-Schwoerer S, Crugnola M, Di Renzo N, Lemoli R, Mattei D,
Fiedler W, et al: Bemcentinib as monotherapy and in combination
with low-dose cytarabine in acute myeloid leukemia patients unfit
for intensive chemotherapy: A phase 1b/2a trial. Nat Commun.
16(2846)2025.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Li H, Liu Z, Liu L, Zhang H, Han C, Girard
L, Park H, Zhang A, Dong C, Ye J, et al: AXL targeting restores
PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through
expansion of TCF1+ CD8 T cells. Cell Rep Med.
3(100554)2022.PubMed/NCBI View Article : Google Scholar
|
